Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, March 30, 2023
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
Wed, March 29, 2023
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
[ Wed, Mar 29th 2023
] - WOPRAI
Gregory Fraser Maintained (ARQT) at Strong Buy with Decreased Target to $45 on, Mar 29th, 2023
Gregory Fraser of Truist Securities, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Strong Buy with Decreased Target from $50 to $45 on, Mar 29th, 2023.
Gregory has made no other calls on ARQT in the last 4 months.
There are 2 other peers that have a rating on ARQT. Out of the 2 peers that are also analyzing ARQT, 0 agree with Gregory's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Gregory
- Serge Belanger of "Needham" Maintained at Strong Buy with Decreased Target to $24 on, Thursday, March 16th, 2023
- Vikram Purohit of "Morgan Stanley" Maintained at Buy with Decreased Target to $50 on, Wednesday, March 1st, 2023
